Real-World Effectiveness of Tixagevimab and Cilgavimab (Evusheld) in Patients With Hematological Malignancies

BACKGROUND: Immunocompromised individuals with hematological malignancy have increased risk for poor outcomes and death from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This special population may mount a suboptimal response to vaccination. We assessed the effectiveness of tixagevi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ocon, Anthony J., Ocon, Kate E., Battaglia, Jennifer, Low, Soon Khai, Neupane, Niraj, Saeed, Hassan, Jamshed, Saad, Mustafa, S. Shahzad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822659/
https://www.ncbi.nlm.nih.gov/pubmed/36632574
http://dx.doi.org/10.14740/jh1062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822659/
https://www.ncbi.nlm.nih.gov/pubmed/36632574
http://dx.doi.org/10.14740/jh1062

Ejemplares similares